Home Cart Sign in  
Chemical Structure| 1951483-29-6 Chemical Structure| 1951483-29-6

Structure of Temuterkib
CAS No.: 1951483-29-6

Chemical Structure| 1951483-29-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY3214996 can inhibit ERK1 and ERK2 with IC50s of 5 nM.

Synonyms: LY3214996

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Temuterkib

CAS No. :1951483-29-6
Formula : C22H27N7O2S
M.W : 453.56
SMILES Code : O=C1C(C=C(C2=NC(NC3=CC=NN3C)=NC=C2)S4)=C4C(C)(C)N1CCN5CCOCC5
Synonyms :
LY3214996
MDL No. :MFCD31544324
InChI Key :JNPRPMBJODOFEC-UHFFFAOYSA-N
Pubchem ID :121408882

Safety of Temuterkib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Temuterkib

MAPK

Isoform Comparison

Biological Activity

Target
  • ERK2

    ERK2, IC50:5 nM

  • ERK1

    ERK1, IC50:5 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-468 0.1 nM–1 µM over 10–14 days To evaluate the synergistic effect with AKT inhibitor VIII, the combination of Temuterkib and Erlotinib showed potential weak synergy in the 468HR model PMC10525382
NIH3T3 cells 5 μM 48 h To study the inhibitory effect of Temuterkib on ERK1/2 and its impact on Per2 nucleocytoplasmic distribution PMC11786901
SMS-CTR cells 100 nM 72 h To evaluate the effect of ERK inhibitor LY3214996 on the growth of H/NRASQ61X mutant FN-RMS cells. The results showed that LY3214996 alone had limited effect on cell growth, but the combination with MEK inhibitor (e.g., trametinib) significantly inhibited ERK activity and induced cell cycle arrest, myogenic differentiation, and apoptosis PMC8742779
RD cells 100 nM 72 h To evaluate the effect of ERK inhibitor LY3214996 on the growth of H/NRASQ61X mutant FN-RMS cells. The results showed that LY3214996 alone had limited effect on cell growth, but the combination with MEK inhibitor (e.g., trametinib) significantly inhibited ERK activity and induced cell cycle arrest, myogenic differentiation, and apoptosis PMC8742779
satellite cells 5 μM 24 h To evaluate the effect of LY3214996 on satellite cell proliferation. The results showed that LY3214996 significantly reduced satellite cell proliferation, and this effect was more pronounced under CR PMC11075744

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice BA-induced cholemia model Intracephalic injection 0.2 μM Single injection To study the reversal effect of Temuterkib on BA-induced circadian rhythm disorders PMC11786901
C.B-Igh-1b/IcrTac-Prkdcscid female mice H/NRASQ61X rhabdomyosarcoma xenograft model Oral or intraperitoneal injection 50 mg/kg Once daily for 28 days Evaluate the inhibitory effect of MEK and ERK inhibitor combination therapy on tumor growth PMC8742779

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04081259 Acute Myeloid Leukemia PHASE1 RECRUITING 2025-04-30 Dana Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.20mL

0.44mL

0.22mL

11.02mL

2.20mL

1.10mL

22.05mL

4.41mL

2.20mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories